SCHEMBL3562210

SCHEMBL3562210

O=C(O)c1ccc(CI)o1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 5/20 0.67
POLB P06746 9/20 0.55
L3MBTL1 Q9Y468 2/20 0.50
MAPT P10636 2/20 0.50
HTT P42858 1/20 0.50
SMN1; SMN2 Q16637 3/20 0.49
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
KMT2A Q03164 2/20 0.49
MAPK1 P28482 1/20 0.49
HSD17B10 Q99714 1/20 0.49
ALDH1A1 P00352 2/20 0.47
ESR1 P03372 1/20 0.47
NR4A1 P22736 1/20 0.47
APEX1 P27695 1/20 0.47
RECQL P46063 1/20 0.47
DUSP3 P51452 1/20 0.47
PTPN5 P54829 1/20 0.47
PTPN11 Q06124 1/20 0.47
ESR2 Q92731 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8610246 0.84 TDP1 (0.69) TDP1POLBL3MBTL1MAPTHTT
SCHEMBL901472 0.82 TDP1 (0.72) TDP1POLBL3MBTL1MAPTHTT
Sumiki'S Acid SCHEMBL29706392 0.80 TDP1 (1.00) TDP1POLBL3MBTL1MAPTHTT
Sumiki'S Acid SCHEMBL50822 0.80 TDP1 (1.00) TDP1POLBL3MBTL1MAPTHTT
SCHEMBL1912549 0.78 TDP1 (0.67) TDP1POLBL3MBTL1MAPTHTT
SCHEMBL18554594 0.78 TDP1 (0.67) TDP1POLBL3MBTL1MAPTHTT
SCHEMBL1669583 0.78 TDP1 (0.67) TDP1POLBL3MBTL1MAPTHTT
SCHEMBL266172 0.78 TDP1 (0.67) TDP1POLBL3MBTL1MAPTHTT
SCHEMBL9484523 0.78 TDP1 (0.67) TDP1POLBL3MBTL1MAPTHTT
SCHEMBL4442918 0.78 TDP1 (0.67) TDP1POLBL3MBTL1MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015179088-A1 CONVERSION OF 5-(HALOMETHYL)-2-FURALDEHYDE INTO POLYESTERS OF 5-METHYL-2FUROIC ACID XF TECHNOLOGIES INC. (US) 2015-11-26 WO disclosed
US-7842825-B2 Biaryloxymethylarenecarboxylic acids as glycogen synthase activator HOFFMANN-LA ROCHE INC. (US) 2010-11-30 US disclosed
US-7700632-B2 Biaryloxymethylarenecarboxylic acids as glycogen synthase activator HOFFMANN-LA ROCHE INC. (US) 2010-04-20 US disclosed
US-20090156635-A1 BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATORS GILLESPIE PAUL 2009-06-18 US disclosed
US-20080255198-A1 BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATOR CHU CHANG AN 2008-10-16 US disclosed
US-20080108662-A1 BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATOR CHU CHANG A 2008-05-08 US disclosed
US-7355049-B2 Biaryloxymethylarenecarboxylic acids as glycogen synthase activator HOFFMANN-LA ROCHE INC. (US) 2008-04-08 US disclosed
US-20060122256-A1 Biaryloxymethylarenecarboxylic acids as glycogen synthase activators GILLESPIE PAUL 2006-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156635-A1 BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATORS GYS2, GYS1, GSK3A TDP1 2573/4885POLB 2071/4885L3MBTL1 3838/4885
US-20060122256-A1 Biaryloxymethylarenecarboxylic acids as glycogen synthase activators GYS2, GYS1, GSK3A TDP1 2573/4885POLB 2071/4885L3MBTL1 3838/4885
US-20080108662-A1 BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATOR GYS2, PYGL, GYS1 TDP1 1948/4885POLB 1685/4885L3MBTL1 3207/4885
US-20080255198-A1 BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATOR GYS2, PYGL, GYS1 TDP1 1948/4885POLB 1685/4885L3MBTL1 3207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.